We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Biogen (BIIB), Sage Finish Zuranolone NDA Filing for Depression
Read MoreHide Full Article
Biogen (BIIB - Free Report) and partner Sage Therapeutics (SAGE - Free Report) completed the rolling submission of the new drug application (NDA) to the FDA for zuranolone for the potential treatment of major depressive disorder (MDD) and postpartum depression (PPD). The NDA submission for this 14-day short course, rapid-acting, oral investigational drug was initiated in May.
The NDA included data from two development programs — LANDSCAPE and NEST. Clinical data on zuranolone demonstrated that the candidate achieved consistent, rapid, and sustained reductions in depressive symptoms with a good safety profile. The LANDSCAPE program includes five studies of zuranolone in adults with MDD, while the NEST program comprised two studies in adult women with PPD
Biogen’s stock has risen 21.4%, while Sage Therapeutics’ stock has declined 2.2% this year so far. The industry has declined 18.7% in the said time frame.
Image Source: Zacks Investment Research
The depression medicines available presently take a lot of time, sometimes weeks and months to provide relief from symptoms. Biogen/Sage believe zuranolone, if approved, can change the way depression is treated as it has a novel mechanism of action, which may help to rapidly rebalance dysregulated neuronal networks and improve brain function.
We note that Sage and Biogen entered into a global collaboration and license agreement for developing and commercializing potential breakthrough therapies in depression and movement disorders in November 2020. The agreement included the development of two candidates from Sage Therapeutics’ pipeline — zuranolone and SAGE-324. The mid-stage candidate, SAGE-324, is being developed for treating essential tremors.
Zacks Rank & Key Picks
Biogen has a Zacks Rank #2 (Buy) currently while Sage has a Zacks Rank of 3 (Hold).
Vertex Pharmaceuticals’ stock has risen 41.9% this year so far. Estimates for Vertex’s 2022 earnings have gone up from $14.21 to $14.65 per share, while that for 2023 have increased from $15.09 to $15.62 per share over the past 60 days. Vertex has a four-quarter earnings surprise of 3.16%, on average.
Estimates for Gilead’s 2022 earnings per share have increased from $6.61 per share to $7.09 per share, while that for 2023 have increased from $6.49 per share to $6.80 per share in the past 30 days. Gilead’s stock is up 21.1% in the year-to-date period.
Gilead beat earnings expectations in three of the trailing four quarters. The company delivered a four-quarter earnings surprise of 0.36%, on average.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
Biogen (BIIB), Sage Finish Zuranolone NDA Filing for Depression
Biogen (BIIB - Free Report) and partner Sage Therapeutics (SAGE - Free Report) completed the rolling submission of the new drug application (NDA) to the FDA for zuranolone for the potential treatment of major depressive disorder (MDD) and postpartum depression (PPD). The NDA submission for this 14-day short course, rapid-acting, oral investigational drug was initiated in May.
The NDA included data from two development programs — LANDSCAPE and NEST. Clinical data on zuranolone demonstrated that the candidate achieved consistent, rapid, and sustained reductions in depressive symptoms with a good safety profile. The LANDSCAPE program includes five studies of zuranolone in adults with MDD, while the NEST program comprised two studies in adult women with PPD
Biogen’s stock has risen 21.4%, while Sage Therapeutics’ stock has declined 2.2% this year so far. The industry has declined 18.7% in the said time frame.
Image Source: Zacks Investment Research
The depression medicines available presently take a lot of time, sometimes weeks and months to provide relief from symptoms. Biogen/Sage believe zuranolone, if approved, can change the way depression is treated as it has a novel mechanism of action, which may help to rapidly rebalance dysregulated neuronal networks and improve brain function.
We note that Sage and Biogen entered into a global collaboration and license agreement for developing and commercializing potential breakthrough therapies in depression and movement disorders in November 2020. The agreement included the development of two candidates from Sage Therapeutics’ pipeline — zuranolone and SAGE-324. The mid-stage candidate, SAGE-324, is being developed for treating essential tremors.
Zacks Rank & Key Picks
Biogen has a Zacks Rank #2 (Buy) currently while Sage has a Zacks Rank of 3 (Hold).
Some large biotech stocks worth considering are Vertex Pharmaceuticals (VRTX - Free Report) and Gilead Sciences (GILD - Free Report) , both carrying a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Vertex Pharmaceuticals’ stock has risen 41.9% this year so far. Estimates for Vertex’s 2022 earnings have gone up from $14.21 to $14.65 per share, while that for 2023 have increased from $15.09 to $15.62 per share over the past 60 days. Vertex has a four-quarter earnings surprise of 3.16%, on average.
Estimates for Gilead’s 2022 earnings per share have increased from $6.61 per share to $7.09 per share, while that for 2023 have increased from $6.49 per share to $6.80 per share in the past 30 days. Gilead’s stock is up 21.1% in the year-to-date period.
Gilead beat earnings expectations in three of the trailing four quarters. The company delivered a four-quarter earnings surprise of 0.36%, on average.